Do the physical and histologic features and time course in acute generalized exanthematous pustulosis reflect a pattern of cytokine dysregulation?

Journal of Cutaneous Medicine and Surgery

Volumn 7, Issue 1, 2003, Pages 7-12

  Smith, Kathleen ^a   Norwood, Christopher ^b   Skelton, Henry ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXAPINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFALEXIN; CYTOKINE; DILTIAZEM; ERYTHROMYCIN; IOPAMIDOL; ITRACONAZOLE; MINOCYCLINE; NYSTATIN; TERBINAFINE;

ACUTE DISEASE; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENTERITIS; FEMALE; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOREGULATION; MALE; MULTIPLE SCLEROSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PSORIASIS; PUSTULOSIS; QUESTIONNAIRE; RASH; SARCOIDOSIS; SKIN BIOPSY; SKIN EDEMA;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYTOKINES; EXANTHEMA; FEMALE; HUMANS; IMMUNE SYSTEM DISEASES; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0347926359     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-002-1151-9     Document Type: Article

References (41)

1. Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Arch Dermatol 1991; 127:1333-1338.
2. Manders SM, Heymann WR. Acute generalized exanthemic pustulosis. Cutis 1994; 54:194-196.
3. Kuchler A, Hamm H, Weidenthaler-Barth B, et al. Acute generalized exanthematous pustulosis following oral nystatin therapy: a report of three cases. Br J Dermatol 1997; 137:808-811.
4. Trueb RM, Burg G. Acute generalized exanthematous pustulosis due to doxycycline. Dermatology. 1993; 186:75-78.
5. Hall AP, Tate B. Acute generalized exanthematous pustulosis associated with oral terbinafine. Australas J Dermatol 2000; 41:42-45.
6. Young PC, Turiansky GW, Bonner MW, et al. Acute generalized pustulosis induced by chromium picolinate. J Am Acad Dermatol 1999; 41:820-823.
7. Lee AY, Yoo SH. Chloramphenicol induced acute generalized exanthematous pustulosis proved by patch test and systemic provocation. Acta Derm Venereol 1999; 79:412-413.
8. Kawaguchi M, Mitsuhashi Y, Kondo S. Acute generalized exanthematous pustulosis induced by salazosulfpyridine in a patient with ulcerative cholitis. J Dermatol 1999; 26:359-362.
9. Bosonnet S, Dandurand M, Moati L, et al. Acute generalized exanthematic pustulosis after intake of clozapine (leponex). Ann Dermatol Venereol 1997; 124:547-548.
10. Koumantald-Mathioudaki E, Papadavid E, Katsambas A. Generalized pustular drug eruptions: confirmation by its in vitro tests. J Eur Acad Dermatol Venereol 1999; 12:196-197.
11. Feio AB, Apetato M, Costa MM, et al. Acute generalized exanthematous pustulosis due to Coxsackie B4. Acta Med Port 1997; 10:487-491.
12. Park YM, Kim JW, Kim CW. Acute generalized exanthematous pustulosis induced by itraconazole. J Am Acad Dermatol 1997; 36:794-796.
13. Beylot C, Doutre MS, Beylot-Barry M. Acute generalized exanthematous pustulosis. Semin Cutan Med Surg 1996; 15:244-249.
14. Haro-Gabaldon V, Sanchez-Sanchez-Vizcaino J, Ruiz-Avila P, et al. Acute generalized exanthematous pustulosis with cytomegalovirus infection. Int J Dermatol 1996; 35:735-737.
15. Jan V, Machet L, Geironet N, et al. Acute generalized exanthematous pustulosis induced by diltiazem: value of patch testing. Dermatology 1998; 197:274-275.
16. Beylot C, Bioulac P, Doutre MS. Pustuloses exanthematiques aigues generalisees: a propos de 4 cas. Ann Dermatol Venereol 1980; 107:37-48.
17. Agostini C, Semenato G. Cytokines in sarcoidosis. Semin Respir Infect 1998; 13:184-196.
18. Austin LM, Orawa M, Kikuchi T, et al. The majority of epidermal T cells in psoriasis vulgaris lesion can produce type 1 cytokines, interferon gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113:752-759.
19. Balashov KE, Comabella M, Ohashi T, et al. Defective regulation of IFNgamma and IL-12 by endogenous progressive MS. Neurology 2000; 55:192-198.
20. Mariani P, Bachetori A, D'Alessandro M, et al. Th-1 cells with cytotoxic function in the intestinal lamina propria of patients with Crohn's disease. Dig Dis Sci 2000; 45:2029-2035.
21. Drugain D, Negru S, Koreck A, et al. The pattern of a T(H)1 cytokine in autoimmune thyroiditis. Immunol Lett 2000; 71:73-77.
22. Syrbe U, Siveke J, Hamann A. Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression? Springer Semin Immunopathol 1999; 21:263-285.
23. Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113:752-759.
24. DeRie MA. Interleukin 12 and psoriasis. Dermatology. 1999; 199:101.
25. Wolf R, Ruocco B. Triggered psoriasis. Adv Exp Med Biol 1999; 455:221-225.
26. Halvey S, Livni E. Beta-adrenergic blocking drugs and psoriasis: the role of an immunologic mechanism. J Am Acad Dermatol 1993; 29:504-505.
27. Robowsky-Kochan C, Molinaro D, Cook SD. Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis. Mult Scler 2000; 6:69-77.
28. Michetti P. Intestinal pathogen or IBD, same T-cell response. Inflamm Bowel Dis 2000; 6:63-64.
29. Agostini C, Trentin L, Perin A, et al. Regulation of alveolar macrophage T cell interactions during Thl type sarcoid inflammatory process. Am J Physiol 1999; 277:240-250.
30. Giasuddin AS, El-Orfi AH, Ziu MM, et al. Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol 1998; 39:940-943.
31. Kalmus Y, Kovatz S, Shilo L, et al. Sweet's syndrome and subacute thyroiditis. Postgrad Med J 2000; 76:229-230.
32. Loraas A, Waage A, Lamvik J. Cytokine response pattern in Sweet's syndrome associated with myelodysplasia. Br J Haematol 1994; 87:669.
33. Arbetter KR, Hubbard KW, Markovic SN, et al. Case of granulocytic colony-stimulating factor-induced Sweet's syndrome. Am J Hematol 1999; 61:126-129.
34. Prud'homme GJ, Piccirillo CA. The inhibitory effects of transforming growth factor beta 1 (TGF-B1) in autoimmune disease. J Autoimmun 2000; 14:23-42.
35. Torri O, Ruto F, Dierick A, et al. Acute febrile neutrophilic dermatitis (Sweet's syndrome) during therapeutic agranulocytosis in acute myeloblastic leukemia. Ann Dermatol Venereol 1993; 120:884-888.
36. Tadokoro CE, Abrahamsohn A. Bone marrow-derived macrophages grown in GM-CSF or M-CSF differ in their ability to produce IL-12 and to induce IFN-Γ production after stimulation with Trypanosoma cruzi antigens. Immunol Lett 2001; 77:31-38.
37. Koss K, Satsangi J, Fanning GC, et al. Cytokine (TNF alpha, LT alpha, and IL-10) polymorphism in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000; 1:185-190.
38. Yamaguchi E, Itoh A, Hizawa N, et al. The gene polymorphism of tumor necrosis factor-beta, but not that of tumor necrosis factor-alpha, is associated with the prognosis of sarcoidosis. Chest 2001; 119:678-679.
39. Martinez A, Fernandez-Arquero M, Pascual-Salcedo D, et al. Primary association of tumor necrosis factor-region genetic markers with susceptibility to rheumatoid arthritis. Arthritis Rheum 2000; 43:1366-1370.
40. McDonnell GV, Kirk CW, Middleton D, et al. Genetic association studies of tumour necrosis factor alpha and beta and tumour necrosis factor receptor 1 and 2 polymorphism across the clinical spectrum of multiple sclerosis. J Neurol 1999; 246:1051-1058.
41. Craven NM, Jackson CW, Kirby B, et al. Cytokine gene polymorphisms in psoriasis. Br J Dermatol 2001; 144:849-853.